Evaluation of estrogen receptor α and β and progesterone receptor expression and correlation with clinicopathologic factors and proliferative marker Ki-67 in breast cancers

Human Pathology

Volumn 39, Issue 5, 2008, Pages 720-730

  Rosa, Fabíola E ^a   Caldeira, José R F ^a,b   Felipes, Joice ^c   Bertonha, Fernanda B ^a   Quevedo, Francisco C ^b   Domingues, Maria A C ^a   Moraes Neto, Francisco A ^b   Rogatto, Silvia R ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b Amaral Carvalho Hospital   (Brazil)

^c STATE UNIVERSITY OF MARINGÁ   (Brazil)

Author keywords

Breast cancer; Estrogen receptor; Immunohistochemistry; mRNA expression; Progesterone receptor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; KI 67 ANTIGEN; MESSENGER RNA; PROGESTERONE RECEPTOR; TUMOR MARKER;

ADULT; ARTICLE; BRAZIL; BREAST CANCER; BREAST CARCINOMA; CANCER SIZE; CONTROLLED STUDY; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE; MAJOR CLINICAL STUDY; PROGNOSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MIDDLE AGED; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 42649138579     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2007.09.019     Document Type: Article

References (49)

1. Esteva F.J., and Hortobagyi G.N. Prognostic molecular markers in early breast cancer. Breast Cancer Res 6 (2004) 109-118
2. Hopp T.A., Weiss H.L., Parra I.S., et al. Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer. Clin Cancer Res 10 (2004) 7490-7499
3. Early Breast Cancer Trialists Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339 (1992) 1-15
4. Baum M., Buchanan M., Baselga J., et al. The future of breast cancer research in danger. Eur J Cancer 38 (2002) 2210-2213
5. Pearce S.T., and Jordan V.C. The biological role of estrogen receptors α and β in cancer. Crit Rev Oncol Hematol 50 (2004) 3-22
6. Kuiper G.G., Enmark E., Pelto-Huikko M., Nilsson S., and Gustafsson J.A. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci U S A 93 (1996) 5925-5930
7. Mosselman S., Polman J., and Dijkema R. ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett 392 (1996) 49-53
8. Enmark E., Pelto-Huikko M., Grandien K., et al. Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern. J Clin Endocrinol Metab 82 (1997) 4258-4265
9. Paech K., Webb P., Kuiper G.G., et al. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 277 (1997) 1508-1510
10. Gustafsson J.A., and Warner M. Estrogen receptor beta in the breast: role in estrogen responsiveness and development of breast cancer. J Steroid Biochem Mol Biol 74 (2000) 245-248
11. Surowiak P., Dziegiel P., Zabel M., Matkowski R., and Kornafel J. Analysis of estrogen receptor (ER) and estrogen-dependent pS2 protein expression in cells of mammary ductal carcinoma. Folia Histochem Cytobiol 39 (2001) 141-142
12. Zaslawski R., Surowiak P., Dziegiel P., Pretnik L., and Zabel M. Analysis of the expression of estrogen and progesteron receptors, and of PCNA and Ki-67 proliferation antigens, in uterine myomata cells in relation to the phase of the menstrual cycle. Med Sci Monit 7 (2005) 908-913
13. Keshgegian A.A., and Cnaan A. Estrogen receptor-negative, progesterone receptor-positive breast carcinoma: poor clinical outcome. Arch Pathol Lab Med 120 (1996) 970-973
14. Beato M. Gene regulation by steroid hormones. Cell 56 (1989) 335-344
15. Ing N.H., Beekman J.M., Tsai S.Y., Tsai M.J., and O'Malley B.W. Members of the steroid hormone receptor superfamily interact with TFIIB (S300-II). J Biol Chem 267 (1992) 17617-17623
16. Klinge C.M. Estrogen receptor interaction with co-activators and co-repressors. Steroids 65 (2000) 227-251
17. Köhler T., Laßner D., Rost A.K., et al. Quantitation of mRNA by polymerase chain reaction: nonradioactive PCR methods (1995), Springer-Verlag, Berlin
18. Ninomiya I., Endo Y., Yonemura Y., and Sasaki T. Reverse transcription/quantitative PCR to detect changes in gene expression in disease. In: Latchman D.S. (Ed). PCR Applications in pathology: principles and practice (1995), Oxford University Press, New York
19. World Health Organization. International of diseases for oncology. 2nd ed. (1990), World Health Organization, Geneva
20. União Internacional Contra o Câncer. Classificação dos tumores malignos. 5th ed. (1998), Ministério da Saúde, Rio de Janeiro-Brasil
21. Bloom M.J.C., and Richardson W.W. Histologic grading and prognosis in breast cancer: a study of 1709 cases. Br J Cancer 11 (1957) 358-377
22. Ariga N., Suzuki T., Moriya T., et al. Progesterone receptor A and B isoforms in the human breast and its disorders. Jpn J Cancer Res 92 (2001) 302-308
23. Weikel W., Beck T., Mitze M., and Knapstein P.G. Immunohistochemical evaluation of growth fractions in human breast cancers using monoclonal antibody Ki-67. Breast Cancer Res Treat 18 (1991) 149-154
24. Bièche I., Parfait B., Laurendeau I., Girault I., Vidaud M., and Lidereau R. Quantification of estrogen receptor alpha and beta expression in sporadic breast cancer. Oncogene 20 (2001) 8109-8115
25. de Cremoux P., Tran-Perennou C., Elie C., et al. Quantitation of estradiol receptors alpha and beta and progesterone receptors in human breast tumors by real-time reverse transcription-polymerase chain reaction. Correlation with protein assays. Biochem Pharmacol 64 (2002) 507-515
26. Jarzabek K., Koda M., Kozlowski L., et al. Distinct mRNA, protein expression patterns and distribution of estrogen receptors α and β in human primary breast cancer: correlation with proliferative marker Ki-67 and clinicopathological factors. Eur J Cancer 41 (2005) 2924-2934
27. Labuhn M., Vuaroqueaux V., Fina F., et al. Simultaneous quantitative detection of relevant biomarkers in breast cancer by quantitative real-time PCR. Int J Biol Markers 21 (2006) 30-39
28. Shaw J.A., Udokang K., Mosquera J.M., et al. Oestrogen receptors alpha and beta differ in normal human breast and breast carcinomas. J Pathol 198 (2002) 450-457
29. Omoto Y., Kobayashi S., Inoue S., et al. Evaluation of oestrogen receptor beta wild-type and variant protein expression, and relationship with clinicopathological factors in breast cancers. Eur J Cancer 38 (2002) 380-386
30. Saji S., Hirose M., and Toi M. Clinical significance of estrogen receptor β in breast cancer. Cancer Chemother Pharmacol 56 (2005) s21-s26
31. Murphy L.C., Leygue E., Niu Y., Snell L., Ho S.M., and Watson P.H. Relationship of coregulator and oestrogen receptor isoform expression to de novo tamoxifen resistance in human breast cancer. Br J Cancer 87 (2002) 1411-1416
32. Dotzlaw H., Leygue E., Watson P.H., and Murphy L.C. Expression of estrogen receptor-beta in human breast tumors. J Clin Endocrinol Metab 82 (1997) 2371-2374
33. Speirs V., and Kerin M.J. Prognostic significance of oestrogen receptor beta in breast cancer. Br J Surg 87 (2000) 405-409
34. Nakopoulou L., Lazaris A.C., Panayotopoulou E.G., et al. The favourable prognostic value of oestrogen receptor beta immunohistochemical expression in breast cancer. J Clin Pathol 57 (2004) 523-528
35. Cullen R., Maguire T.M., McDermott E.W., et al. Studies on oestrogen receptor-alpha and -beta mRNA in breast cancer. Eur J Cancer 37 (2001) 1118-1122
36. Simpson P.T., Reis-Fiho J.S., Gale T., and Lakhani S. Molecular evolution of breast cancer. J Pathol 205 (2005) 248-254
37. Remvikos Y., Beuzeboc P., Zajdela A., et al. Correlation of pretreatment proliferative activity of breast cancer with the response to cytotoxic chemotherapy. J Natl Cancer Inst 81 (1989) 1383-1387
38. Bottini A., Berruti A., Bersiga A., et al. Effect of neoadjuvant chemotherapy on Ki67 labelling index, c-erbB-2 expression and steroid hormone receptor status in human breast tumours. Anticancer Res 16 (1996) 3105-3110
39. Collecchi P., Baldini E., Giannessi P., et al. Primary chemotherapy in locally advanced breast cancer (LABC): effects on tumour proliferative activity, bcl-2 expression and the relationship between tumour regression and biological markers. Eur J Cancer 34 (1998) 1701-1714
40. Jalava P., Kuopio T., Juntti-Patinen L., Kotkansalo T., Kronqvist P., and Collan Y. Ki67 immunohistochemistry: a valuable marker in prognostication but with a risk of misclassification: proliferation subgroups formed based on Ki67 immunoreactivity and standardized mitotic index. Histopathology 48 (2006) 674-682
41. Burcombe R.J., Makris A., Richman P.I., et al. Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. Br J Cancer 92 (2005) 147-155
42. Ding S.L., Sheu L.F., Yu J.-C., et al. Expression of estrogen receptor-α and Ki67 in relation to pathological and molecular features in early-onset infiltrating ductal carcinoma. J Biomed Sci 11 (2004) 911-919
43. Tan P.-H., Bay B.-H., Yip G., et al. Immunohistochemical detection of Ki67 in breast cancer correlates with transcriptional regulation of genes related to apoptosis and cell death. Mod Pathol 18 (2005) 374-381
44. Skliris G.P., Leygue E., Curtis-Snell L., Watson P.H., and Murphy L.C. Expression of oestrogen receptor-beta in oestrogen receptor-alpha negative human breast tumours. Br J Cancer 95 (2006) 616-626
45. Jarvinen T.A.H., Pelto-Huikko M., Holli K., et al. Estrogen receptor beta is co-expressed with ERalpha and PR and associated with nodal status, grade, and proliferation in breast cancer. Am J Pathol 156 (2000) 29-35
46. Gago F.E., Fanelli M.A., and Ciocca D.R. Co-expression of steroid hormone receptors (estrogen receptor alpha and/or progesterone receptors) and Her2/neu (c-erbB-2) in breast cancer: clinical outcome following tamoxifen-based adjuvant therapy. J Steroid Biochem Mol Biol 98 (2006) 36-40
47. Lakhani S.R. The pathology of familial breast cancer: morphological aspects. Breast Cancer Res 1 (1999) 31-35
48. Loman N., Johannsson O., Bendahl P.O., Borg A., Fernö M., and Olsson H. Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes. Cancer 83 (1998) 310-319
49. Eerola H., Heikkila P., Tamminen A., Aittomaki K., Blomqvist C., and Nevanlinna H. Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer families. Breast Cancer Res 7 (2005) R93-R100